\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes MSCA Horizon EuropeThe EU-funded SAFE project “Supporting At-risk researchers with Fellowships in Europe” offers up to 60 fellowships for at-risk doctoral and postdoctoral researchers of any non-EU nationality for a research stay at a higher education and research institution in the EU for a minimum of 12 months up to 24 months.
For the selection process they are in search of international experts to evaluate applications in the period mid-February until mid-March 2025 (expected), based on the project’s evaluation criteria. They are specifically in search of:
Further details about the requirements and responsibilities of reviewers can be found in the Terms of Reference for External Reviewers which can be found on the webpage of the call for external reviewers. The Terms of Reference for Applicants for the Fellowships can be found on the webpage for online application.
Interested experts can submit their expression of interest via this link until 31 January 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Cybersecurity Defence EDF
We hereby want you to give an overview of the known activities related to the EDF 2025 calls: Publication of the European Defence Fund (EDF) Work Programme 2025 infosessions: Belgian and Flanders EDF infoday on February 21st in Brussels The EDF Info Days 2025 will take place on 2-3 April in hybrid format in&n... read more
Digital, Industry & Space AI, data & cloud Deployment: Best use of technologies
The European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. The AI Act, which aims to promote innovation while... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
